Identification of a rare polymorphism in the human TP53 promoter

被引:4
|
作者
Attwooll, CL
McGown, G
Thorncroft, M
Stewart, FJ
Birch, JM
Varley, JM
机构
[1] Paterson Inst Canc Res, CRC Dept Canc Genet, Manchester M20 4BX, Lancs, England
[2] Belfast City Hosp, No Ireland Reg Genet Serv, Belfast BT9 7AB, Antrim, North Ireland
[3] Royal Manchester Childrens Hosp, CRC Paediat & Familial Canc Res Grp, Manchester M27 1HA, Lancs, England
基金
英国医学研究理事会;
关键词
D O I
10.1016/S0165-4608(01)00649-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The majority of families with classic Li-Fraumeni Syndrome (LFS) and a significant proportion of Li-Fraumeni-like (LFL) families have a germline mutation in the TP53 tumor suppressor gene. However around 20% of LFS and 60% of LFL families have no identifiable genetic defect in the coding region or splice junctions of TP53, and the genetic basis for cancer susceptibility in these families remains largely uncharacterized. To determine whether promoter mutations could be responsible for the Li-Fraumeni phenotype, we sequenced the TP53 promoter in index cases from members of classic LFS and LFL families without detectable TP53 mutations. We identified an identical single nucleotide deletion within the C/EBP-like site of the promoter in two out of eighteen such families (11%), compared to only one of a total of 366 control samples (0.3%). Although this result is highly significant (P=0.006, Fischer's exact test), the mutation did not affect the expression of TP53 in our hands. We provide evidence that this site is not utilized in the wild type TP53 promoter and further, that mutation of this site in LFS/LFL does not have a functional effect. We conclude that the sequence variant is a rare polymorphism arising within the TP53 promoter. However, the significantly increased frequency of this variant in LFS/LFL remains intriguing. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:165 / 172
页数:8
相关论文
共 50 条
  • [1] TP53 promoter methylation in human gliomas
    Amatya, VJ
    Naumann, U
    Weller, M
    Ohgaki, H
    ACTA NEUROPATHOLOGICA, 2005, 110 (02) : 178 - 184
  • [2] TP53 promoter methylation in human gliomas
    Vishwa Jeet Amatya
    Ulrike Naumann
    Michael Weller
    Hiroko Ohgaki
    Acta Neuropathologica, 2005, 110 : 178 - 184
  • [3] Disruption of the TP53 locus in osteosarcoma leads to TP53 promoter gene fusions and restoration of parts of the TP53 signalling pathway
    Saba, Karim H.
    Difilippo, Valeria
    Kovac, Michal
    Cornmark, Louise
    Magnusson, Linda
    Nilsson, Jenny
    van den Bos, Hilda
    Spierings, Diana C. J.
    Bidgoli, Mahtab
    Jonson, Tord
    Sumathi, Vaiyapuri P.
    Brosjoe, Otte
    Staaf, Johan
    Foijer, Floris
    Styring, Emelie
    Nathrath, Michaela
    Baumhoer, Daniel
    Nord, Karolin H.
    JOURNAL OF PATHOLOGY, 2024, 262 (02): : 147 - 160
  • [4] BIALLELIC APAI POLYMORPHISM OF THE HUMAN P53-GENE (TP53)
    PROSSER, J
    CONDIE, A
    NUCLEIC ACIDS RESEARCH, 1991, 19 (17) : 4799 - 4799
  • [5] BSTNI/NCII POLYMORPHISM OF THE HUMAN P53 GENE (TP53)
    CHUMAKOV, PM
    JENKINS, JR
    NUCLEIC ACIDS RESEARCH, 1991, 19 (24) : 6969 - 6969
  • [6] Patterns of structural variants within TP53 introns and relocation of the TP53 promoter: a commentary
    Beird, Hannah C.
    Lin, Dimitri
    Lazar, Alexander J.
    Futreal, P. Andrew
    JOURNAL OF PATHOLOGY, 2024, 263 (02): : 131 - 134
  • [7] TP53 or Not TP53: That Is the Question
    Green, Steven D.
    Zeidner, Joshua F.
    CLINICAL CANCER RESEARCH, 2022, 28 (24) : 5235 - 5237
  • [8] An Ava I polymorphism in the TP53 gene
    Graziani, D
    Romagnoli, S
    Cassani, B
    Alfano, RM
    Roncalli, M
    Coggi, G
    MOLECULAR AND CELLULAR PROBES, 1999, 13 (05) : 393 - 395
  • [9] A polymorphism in intron 2 of the TP53 gene
    DiCioccio, RA
    Piver, MS
    CLINICAL GENETICS, 1996, 50 (02) : 108 - 109
  • [10] AN ALU POLYMORPHISM INTRAGENIC TO THE TP53 GENE
    FUTREAL, PA
    BARRETT, JC
    WISEMAN, RW
    NUCLEIC ACIDS RESEARCH, 1991, 19 (24) : 6977 - 6977